Prof Nicolas Girard speaks to ecancer about the phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts.

Cancer treatment is evolving with a focus on specific patient subsets and effective dosing strategies.

Early administration of targeted agents shows promise, with new data indicating significant treatment outcomes.

The study showed that the safety profile of BAY 2927088 was manageable across cohorts. Treatment with BAY 2927088 led to durable responses in patients naïve to HER2-targeted therapy and those who had received a HER2-targeted ADC.

Advancements in immune checkpoint inhibitors are also highlighted, enhancing patient quality of life and underscoring the importance of multidisciplinary discussions in thoracic oncology.